Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion BCGC-1
2023-509566-38-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of zongertinib in breast cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 2 more (7 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities and Objective response. Planned start Aug 2024; status: authorised.
02
Drugs
zongertinib
03
Conditions
breast cancergastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-509566-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509566-38-00.